Research programme: nicotine receptor agonist - Endovasc

Drug Profile

Research programme: nicotine receptor agonist - Endovasc

Alternative Names: Angiogenix; Nicotine receptor agonist-liposomal; NRA

Latest Information Update: 14 Jun 2005

Price : $50

At a glance

  • Originator Stanford University
  • Developer HERMES BioSciences; Stentgenix
  • Class
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Cardiovascular disorders; Coronary artery restenosis; Heart failure; Peripheral arterial occlusive disorders

Most Recent Events

  • 25 May 2005 Discontinued - Preclinical for Coronary artery restenosis in USA (Implant)
  • 25 May 2005 Discontinued - Preclinical for Peripheral arterial occlusive disorders in USA (Parenteral)
  • 25 May 2005 Discontinued - Preclinical for Alzheimer's disease in Sweden (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top